StageAcquired - II | Acquired
ArcherDX offers a bioinformatics platform for targeted sequencing applications featuring proprietary Anchored Multiplexed PCR (AMP) chemistry in a lyophilized format. On June 22nd, 2020, ArcherDx was acquired by Invitae at a valuation between $325 and $1400M.
Missing: ArcherDx's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: ArcherDx's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing ArcherDx
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
ArcherDx is included in 6 Expert Collections, including Cancer.
Products/services that analyze tumor-derived biomarkers (ctDNA, CTCs, exosomes) in blood/urine/other non-invasive liquid specimens to detect cancer earlier, guide treatment, and monitor progress. *Data fields manually updated as new information becomes available.'
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Health Monitoring & Diagnostics
Companies developing companion diagnostics and technology enabling the development of companion diagnostics. Tagged as #CompanionDx
ArcherDx has filed 19 patents.
The 3 most popular patent topics include:
- Molecular biology
Molecular biology, DNA, Genetics, Biotechnology, DNA sequencing
Molecular biology, DNA, Genetics, Biotechnology, DNA sequencing
Latest ArcherDx News
May 15, 2023
Save for later NEW YORK – A jury in the US District Court for the District of Delaware on Monday awarded Natera $19.4 million in damages for royalties and lost profits in a patent lawsuit against Invitae and ArcherDx. Specifically, the jury found that Invitae and ArcherDx products infringed upon Natera's patents 10,557,172; 10,597,708; and 10,731,220; all related to minimal residual disease. Natera had originally asked for $38 million in damages in a case filed in 2020. While the jury determined that Invitae and ArcherDx, which Invitae acquired in 2020, directly infringed on Natera's patents, it found that they did not indirectly infringe, implying that the defendants in this case were not held responsible for infringement committed by customers. A judge will now decide at an upcoming hearing whether to grant an injunction against Invitae and ArcherDx, or whether to award ongoing royalties. "We are pleased with the jury’s verdict in this case, which underscores our commitment to innovative technology backed by scientific evidence that advances patient care," Natera said in a statement. "The Natera patents asserted against ArcherDx/Invitae in this case are a fraction of an extensive global IP portfolio of more than 360 issued or pending patents, with more than 180 in the field of oncology/MRD. We remain focused on serving the oncology community, including our many physicians and patients."
ArcherDx Frequently Asked Questions (FAQ)
When was ArcherDx founded?
ArcherDx was founded in 2013.
Where is ArcherDx's headquarters?
ArcherDx's headquarters is located at 2477 55th Street, Boulder.
What is ArcherDx's latest funding round?
ArcherDx's latest funding round is Acquired - II.
How much did ArcherDx raise?
ArcherDx raised a total of $150M.
Who are the investors of ArcherDx?
Investors of ArcherDx include Invitae, Longwood Fund, PBM Capital Group, Boulder Ventures, Perceptive Advisors and 9 more.
Who are ArcherDx's competitors?
Competitors of ArcherDx include C2i Genomics.
Compare ArcherDx to Competitors
AIQ Solutions develops an advanced clinical decision support platform based upon advanced analytics, including artificial intelligence, to provide a better understanding of treatment response, and help clinicians more effectively treat complex diseases. The company was founded in 2016 and is based in Madison, Wisconsin.
Genome Insight is a company for whole-genome sequencing (WSG) that provides a view of a patient's entire genetic profile through WGS analysis and interpretation. It offers WGS insights for patients, clinicians, and industries. Its other offerings include population-scale medical whole-genome database creation for precision healthcare. The company was founded in 2020 and is based in La Jolla, California.
C2i Genomics monitors cancer recurrence with whole genome pattern recognition. It offers post-surgery monitoring of cancer recurrence and progression by analyzing subtle changes in the pattern of the tumor’s deoxyribonucleic acid (DNA). It was founded in 2019 and is based in New York.
Natera (NASDAQ: NTRA) operates as a clinical genetic testing company. It develops and commercializes molecular testing services offering a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus as well as twin pregnancies for zygosity, a single-gene mutations screening test to identify single-gene disorder, carrier screening to determine carrier status for various genetic diseases, and more. The company was formerly known as Gene Security Network. The company was founded in 2004 and is based in Austin, Texas.
Guardant Health (NASDAQ: GH) develops genomic cancer testing from a single blood draw. It helps oncologists learn information about patients while avoiding the risks of tissue biopsies and it offers a biopsy-free tumor sequencing test that tracks tumor genomics. The company was founded in 2012 and is based in Redwood City, California.
Inivata is a clinical cancer genomics company focused on harnessing the potential of circulating tumour DNA (ctDNA) analysis to improve cancer testing and treatment. The company is focused on developing clinical applications of ctDNA through collaborations with clinical oncologists at prominent academic institutions, community treatment centres and biopharmaceutical companies. On May 5th, 2021, NeoGenomics acquired a majority stake in Inivata. The terms of the transaction were not disclosed.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.